198 related articles for article (PubMed ID: 33805660)
21. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.
Khare P; Dave KM; Kamte YS; Manoharan MA; O'Donnell LA; Manickam DS
AAPS J; 2021 Dec; 24(1):8. PubMed ID: 34873640
[TBL] [Abstract][Full Text] [Related]
22. Development of siRNA-Loaded Lipid Nanoparticles Targeting Long Non-Coding RNA LINC01257 as a Novel and Safe Therapeutic Approach for t(8;21) Pediatric Acute Myeloid Leukemia.
Connerty P; Moles E; de Bock CE; Jayatilleke N; Smith JL; Meshinchi S; Mayoh C; Kavallaris M; Lock RB
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683974
[TBL] [Abstract][Full Text] [Related]
23. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
24. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
[TBL] [Abstract][Full Text] [Related]
25. Myocardin and myocardin-related transcription factor-A synergistically mediate actin cytoskeletal-dependent inhibition of liver fibrogenesis.
Shi Z; Ren M; Rockey DC
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G504-G517. PubMed ID: 31928221
[TBL] [Abstract][Full Text] [Related]
26. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
[TBL] [Abstract][Full Text] [Related]
27. Production of siRNA-Loaded Lipid Nanoparticles using a Microfluidic Device.
Maeki M; Okada Y; Uno S; Niwa A; Ishida A; Tani H; Tokeshi M
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35404350
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis.
Tagalakis AD; Madaan S; Larsen SD; Neubig RR; Khaw PT; Rodrigues I; Goyal S; Lim KS; Yu-Wai-Man C
J Nanobiotechnology; 2018 Nov; 16(1):97. PubMed ID: 30482196
[TBL] [Abstract][Full Text] [Related]
29. Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment.
Zhang M; Jiang H; Wu L; Lu H; Bera H; Zhao X; Guo X; Liu X; Cun D; Yang M
J Control Release; 2022 Dec; 352():422-437. PubMed ID: 36265740
[TBL] [Abstract][Full Text] [Related]
30. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
[TBL] [Abstract][Full Text] [Related]
31. Myocardin-related transcription factor-A complexes activate type I collagen expression in lung fibroblasts.
Luchsinger LL; Patenaude CA; Smith BD; Layne MD
J Biol Chem; 2011 Dec; 286(51):44116-44125. PubMed ID: 22049076
[TBL] [Abstract][Full Text] [Related]
32. SRF/MRTF-A and liver cirrhosis: Pathologic associations.
Al-Hetty HRAK; Ismaeel GL; Mohammad WT; Toama MA; Kandeel M; Saleh MM; Turki Jalil A
J Dig Dis; 2022 Nov; 23(11):614-619. PubMed ID: 36601855
[TBL] [Abstract][Full Text] [Related]
33. Lipid nanoparticle delivery systems for siRNA-based therapeutics.
Wan C; Allen TM; Cullis PR
Drug Deliv Transl Res; 2014 Feb; 4(1):74-83. PubMed ID: 25786618
[TBL] [Abstract][Full Text] [Related]
34. Lipid Nanoparticle (LNP) Chemistry Can Endow Unique
Johnson LT; Zhang D; Zhou K; Lee SM; Liu S; Dilliard SA; Farbiak L; Chatterjee S; Lin YH; Siegwart DJ
Mol Pharm; 2022 Nov; 19(11):3973-3986. PubMed ID: 36154076
[TBL] [Abstract][Full Text] [Related]
35. On the role of helper lipids in lipid nanoparticle formulations of siRNA.
Kulkarni JA; Witzigmann D; Leung J; Tam YYC; Cullis PR
Nanoscale; 2019 Nov; 11(45):21733-21739. PubMed ID: 31713568
[TBL] [Abstract][Full Text] [Related]
36. In Vivo Endothelial Cell Gene Silencing by siRNA-LNPs Tuned with Lipoamino Bundle Chemical and Ligand Targeting.
Yazdi M; Pöhmerer J; Hasanzadeh Kafshgari M; Seidl J; Grau M; Höhn M; Vetter V; Hoch CC; Wollenberg B; Multhoff G; Bashiri Dezfouli A; Wagner E
Small; 2024 Jun; ():e2400643. PubMed ID: 38923700
[TBL] [Abstract][Full Text] [Related]
37. Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood-brain barrier and glioma cells.
Bruun J; Larsen TB; Jølck RI; Eliasen R; Holm R; Gjetting T; Andresen TL
Int J Nanomedicine; 2015; 10():5995-6008. PubMed ID: 26451106
[TBL] [Abstract][Full Text] [Related]
38. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
[TBL] [Abstract][Full Text] [Related]
39. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts.
Johnson LA; Rodansky ES; Haak AJ; Larsen SD; Neubig RR; Higgins PD
Inflamm Bowel Dis; 2014 Jan; 20(1):154-65. PubMed ID: 24280883
[TBL] [Abstract][Full Text] [Related]
40. Engineered ionizable lipid nanoparticles mediated efficient siRNA delivery to macrophages for anti-inflammatory treatment of acute liver injury.
Zhang H; Ding F; Zhu Z; Sun Q; Yang C
Int J Pharm; 2023 Jan; 631():122489. PubMed ID: 36521639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
